## **Gene Therapy Plus Specific Stop-Loss Rider**

List of Covered Drugs

## **Current FDA-approved drugs covered under the rider:**

- Casgevy
- Hemgenix
- Kymriah—only for treatment of pediatric Acute Lymphoblastic Leukemia
- Luxturna
- Lyfgenia
- Rethymic
- Roctavian
- Skysona
- Zolgensma
- Zynteglo

Medical Mutual is continually monitoring the gene therapy and specialty drug pipelines for future high-impact products that may be added to our Gene Therapy Plus coverage. Examples of conditions with potential upcoming gene therapies in the near-term include sickle cell disease, muscular dystrophy, AADC (Aromatic I-amino acid decarboxylase deficiency) as well as cellular therapies for various cancers.

Note: Effective Aug. 2, 2023, Elevidys is no longer covered.

